NEXT EVENT - Friday, 24th October 2025 - Novotel London West

Hosted by Fraser Thorne, Edison

OpenStage Theatre
2.35 pm

Welcome to Meet the Company 2025, in association with Edison, a new feature at the London Investor Show intended to give delegates an opportunity to hear directly from a selection of exciting UK-listed companies.

This year, Edison present: IXICO and two other exciting UK growth companies (details to be announced shortly).

Meet the Company is hosted by Fraser Thorne, CEO, Edison Group

Companies

IXICO

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech’s, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world. [paragraph] The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Image data is interrogated by the Platform and IXICO’s expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

Read more about the latest IXICO contract win HERE.

Speaker: Bram Goorden

Bram has over 20 years of leadership in BioPharma and precision medicine. He held C-level roles at Eagle Genomics and SOPHiA Genetics, enhancing platform innovation and US presence. As VP at Foundation Medicine, he expanded its global precision medicine platform. As CEO of Prometheus Laboratories, he integrated it into Nestle Health Science and served as Head of Brain Health. Earlier, he held senior roles at UCB Pharma and Eli Lilly, launching CNS medicines globally. Bram’s board experience includes Mantis Photonics and Cerecin Inc. He is passionate about patient care and values diverse teams. His strategic vision and leadership have consistently driven growth and shareholder value.

Diverse Income Trust plc

The aim of this trust is to provide shareholders with an attractive and growing level of dividends, coupled with capital growth over the long term, by investing in quoted UK companies. The investment team, who have manged the trust since 2011, have the flexibility to invest in different sized companies but tend to focus on small and medium sized companies. The trust provides a diverse portfolio across sectors and company size to achieve the growing income objective.

Speaker: Gervais Williams

Gervais Williams joined Premier Miton in March 2011. He is Head of Equities and manages a number of funds and trusts. His fund management career extends over 30 years including 17 years at Gartmore Group Ltd, where he was head of UK Small Companies investing in UK smaller companies and Irish equities. Gervais is a member of the AIM Advisory Council and President of the Quoted Companies Alliance. He was a member of the Patient Capital Review panel with the Chancellor of the Exchequer where the recommendations were put into legislation in the subsequent budget. Gervais has published three books, 'Slow Finance' in the autumn of 2011 (Bloomsbury), 'The Future is Small' was published in November 2014 (Harriman House) and 'The Retreat of Globalisation' published in December 2016 (Harriman House).